US 8334297
2,4-pyrimidinediamine compounds for treatment of inflammatory disorders
granted A61PA61P1/04A61P17/06
Quick answer
US patent 8334297 (2,4-pyrimidinediamine compounds for treatment of inflammatory disorders) held by Rigel Pharmaceuticals, Inc. expires Mon Dec 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Dec 18 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 13 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 26
- CPC classes
- A61P, A61P1/04, A61P17/06, A61P19/02, A61P29/00